BIIB

$253.621.59%3.97

Nachbörslich: 253.60-0.02 -0.01%

Biogen Inc (BIIB)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$249.65

Offen:

$255.39

24-Stunden-Volumen:

1,303,235

Relatives Volumen:

0.93

Marktkapitalisierung:

$37.49B

Einnahmen:

$9.60B

Nettoeinkommen (Verlust:

$1.37B

KGV:

27.22

EPS:

$9.32

Netto-Cashflow:

$2.32B

1W Leistung:

+1.17%

1M Leistung:

+12.28%

6M Leistung:

+33.99%

1Y Leistung:

+69.52%

1-Tages-Spanne:

$251.19$258.73

1-Wochen-Bereich:

$243.03$258.78

52-Wochen-Spanne:

$138.00$258.78

Biogen Inc Aktie (BIIB) Unternehmensprofil

Firmenname

Biogen Inc

Sektor

Healthcare

Branche

Drug Manufacturers - General

Telefon

(781) 464-2000

Adresse

225 BINNEY STREET, CAMBRIDGE, MA, USA

Mitarbeiter

7,500

@biogen

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

BIIB-Diskussionen auf X

BIIB vs. LLY, JNJ, ABBV, MRK, NVS vergleichen

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BIIB Biogen Inc	$253.62	$37.49B	$9.60B	$1.37B	$2.32B	$9.32
LLY Lilly Eli Co	$1,417.54	$1.26T	$72.25B	$25.28B	$10.37B	$27.78
JNJ Johnson Johnson	$273.20	$657.68B	$97.93B	$21.04B	$17.80B	$8.63
ABBV Abbvie Inc	$294.89	$521.11B	$62.82B	$3.60B	$19.98B	$2.03
MRK Merck Co Inc	$149.52	$368.89B	$65.51B	$8.93B	$14.12B	$3.55
NVS Novartis Ag Adr	$160.79	$303.67B	$54.66B	$13.58B	$16.05B	$7.02

Biogen Inc Aktie (BIIB) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-12	Hochstufung	JP Morgan	Neutral → Overweight
2026-08-13	Hochstufung	Wolfe Research	Peer Perform → Outperform
2026-07-13	Hochstufung	Truist	Hold → Buy
2026-06-08	Hochstufung	Needham	Hold → Buy
2026-05-15	Resumed	Evercore ISI	Outperform
2026-04-22	Hochstufung	UBS	Neutral → Buy
2026-04-20	Hochstufung	Wells Fargo	Equal Weight → Overweight
2026-04-14	Hochstufung	Piper Sandler	Neutral → Overweight
2026-02-20	Eingeleitet	Barclays	Equal Weight
2026-02-09	Bestätigt	H.C. Wainwright	Buy
2026-01-07	Resumed	UBS	Neutral
2025-12-10	Herabstufung	HSBC Securities	Hold → Reduce
2025-11-06	Hochstufung	Stifel	Hold → Buy
2025-09-25	Eingeleitet	Jefferies	Buy
2025-07-21	Resumed	Truist	Hold
2025-04-28	Herabstufung	HSBC Securities	Buy → Hold
2025-04-04	Herabstufung	Argus	Buy → Hold
2025-02-11	Eingeleitet	Bernstein	Mkt Perform
2025-01-02	Herabstufung	Piper Sandler	Overweight → Neutral
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-16	Herabstufung	Stifel	Buy → Hold
2024-12-10	Resumed	BofA Securities	Neutral
2024-12-09	Herabstufung	Jefferies	Buy → Hold
2024-11-18	Herabstufung	Needham	Buy → Hold
2024-11-15	Eingeleitet	Wolfe Research	Peer Perform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-10-31	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-10-10	Resumed	Raymond James	Mkt Perform
2024-02-14	Bestätigt	Needham	Buy
2024-02-14	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-01-24	Herabstufung	UBS	Buy → Neutral
2023-12-20	Resumed	Cantor Fitzgerald	Overweight
2023-12-07	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-09-06	Eingeleitet	HSBC Securities	Buy
2023-07-27	Eingeleitet	Scotiabank	Sector Outperform
2023-07-24	Bestätigt	UBS	Buy
2023-05-01	Hochstufung	Guggenheim	Neutral → Buy
2023-04-17	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-26	Hochstufung	Goldman	Neutral → Buy
2022-10-13	Hochstufung	Stifel	Hold → Buy
2022-10-07	Hochstufung	Argus	Hold → Buy
2022-09-28	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-09-28	Hochstufung	Mizuho	Neutral → Buy
2022-09-28	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-04-18	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-03-08	Herabstufung	Stifel	Buy → Hold
2022-03-03	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-02-04	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-04	Bestätigt	Barclays	Equal Weight
2022-02-04	Bestätigt	BofA Securities	Neutral
2022-02-04	Bestätigt	Cowen	Outperform
2022-02-04	Bestätigt	Morgan Stanley	Overweight
2022-02-04	Bestätigt	Needham	Buy
2022-02-04	Bestätigt	Oppenheimer	Outperform
2022-02-04	Bestätigt	RBC Capital Mkts	Sector Perform
2022-02-04	Bestätigt	Robert W. Baird	Neutral
2022-02-04	Bestätigt	Wedbush	Neutral
2022-02-04	Bestätigt	Wells Fargo	Equal Weight
2022-02-04	Bestätigt	Wolfe Research	Peer Perform
2022-01-13	Herabstufung	Guggenheim	Buy → Neutral
2022-01-12	Herabstufung	Piper Sandler	Overweight → Neutral
2021-12-10	Resumed	Raymond James	Mkt Perform
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Eingeleitet	BMO Capital Markets	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-06-18	Hochstufung	Piper Sandler	Neutral → Overweight
2021-06-14	Bestätigt	Truist	Buy
2021-06-11	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-06-10	Hochstufung	UBS	Neutral → Buy
2021-06-08	Hochstufung	Atlantic Equities	Underweight → Neutral
2021-06-08	Bestätigt	Barclays	Equal Weight
2021-06-08	Hochstufung	Citigroup	Sell → Neutral
2021-06-08	Bestätigt	H.C. Wainwright	Buy
2021-06-08	Bestätigt	Jefferies	Buy
2021-06-08	Bestätigt	Morgan Stanley	Overweight
2021-06-08	Bestätigt	RBC Capital Mkts	Sector Perform
2021-06-08	Hochstufung	Robert W. Baird	Underperform → Neutral
2021-06-08	Bestätigt	Stifel	Buy
2021-06-08	Hochstufung	William Blair	Mkt Perform → Outperform
2021-06-07	Hochstufung	BofA Securities	Underperform → Neutral
2021-06-07	Hochstufung	Cowen	Market Perform → Outperform
2021-06-07	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-02-05	Herabstufung	DZ Bank	Buy → Hold
2021-01-29	Hochstufung	Stifel	Hold → Buy
2020-11-10	Hochstufung	DZ Bank	Hold → Buy
2020-11-09	Herabstufung	Atlantic Equities	Neutral → Underweight
2020-11-09	Herabstufung	BofA Securities	Neutral → Underperform
2020-11-09	Herabstufung	Cowen	Outperform → Market Perform
2020-11-09	Bestätigt	H.C. Wainwright	Buy
2020-11-04	Hochstufung	BofA Securities	Underperform → Neutral
2020-11-04	Hochstufung	Jefferies	Hold → Buy
2020-11-04	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-10-28	Eingeleitet	UBS	Neutral
2020-07-27	Hochstufung	Morgan Stanley	Underweight → Overweight
2020-06-22	Herabstufung	Barclays	Overweight → Equal Weight
2020-06-22	Bestätigt	RBC Capital Mkts	Sector Perform
2020-06-09	Herabstufung	Bernstein	Outperform → Mkt Perform
2020-04-23	Herabstufung	Citigroup	Neutral → Sell
2020-04-23	Herabstufung	Raymond James	Mkt Perform → Underperform
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-01-27	Hochstufung	Canaccord Genuity	Hold → Buy
2019-12-13	Hochstufung	Credit Suisse	Underperform → Neutral
2019-12-02	Herabstufung	Robert W. Baird	Neutral → Underperform

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

Nettogewinn

Free Cashflow

ENV

Biogen Inc-Aktie (BIIB) Insiderhandel

Minor LloydAug 04 '26
Director
Transaktion
Proposed Sale
Kosten
$200.96
#Aktien
593
Wert ($)
119,169
#Aktien Gesamt
0
Minor LloydAug 04 '26
Director
Transaktion
Sale
Kosten
$200.96
#Aktien
593
Wert ($)
119,169
#Aktien Gesamt
2,689
Minor LloydAug 03 '26
Director
Transaktion
Sale
Kosten
$203.34
#Aktien
593
Wert ($)
120,581
#Aktien Gesamt
3,282
Minor LloydAug 03 '26
Director
Transaktion
Proposed Sale
Kosten
$203.34
#Aktien
593
Wert ($)
120,581
#Aktien Gesamt
0
Pangalos Menelas NJun 09 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
2,370
Wert ($)
0
#Aktien Gesamt
2,370
Keeney AdamMay 01 '26
Head of Corporate Development
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
939
Wert ($)
0
#Aktien Gesamt
6,820
Godbout SeanApr 01 '26
Chief Accounting Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
181
Wert ($)
0
#Aktien Gesamt
1,396
Murphy NicoleFeb 12 '26
Head of Pharm Ops and Tech
Transaktion
Buy
Kosten
$195.03
#Aktien
3
Wert ($)
585
#Aktien Gesamt
19,611
Singhal PriyaFeb 09 '26
Officer
Transaktion
Proposed Sale
Kosten
$199.83
#Aktien
2,660
Wert ($)
531,548
#Aktien Gesamt
0
Singhal PriyaFeb 09 '26
Head of Development
Transaktion
Sale
Kosten
$199.83
#Aktien
2,660
Wert ($)
531,548
#Aktien Gesamt
8,043

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Minor Lloyd	Director	Aug 04 '26	Proposed Sale	$200.96	593	119,169	0
Minor Lloyd	Director	Aug 04 '26	Sale	$200.96	593	119,169	2,689
Minor Lloyd	Director	Aug 03 '26	Sale	$203.34	593	120,581	3,282
Minor Lloyd	Director	Aug 03 '26	Proposed Sale	$203.34	593	120,581	0
Pangalos Menelas N	Director	Jun 09 '26	Option Exercise	$0.00	2,370	0	2,370
Keeney Adam	Head of Corporate Development	May 01 '26	Option Exercise	$0.00	939	0	6,820
Godbout Sean	Chief Accounting Officer	Apr 01 '26	Option Exercise	$0.00	181	0	1,396
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12 '26	Buy	$195.03	3	585	19,611
Singhal Priya	Officer	Feb 09 '26	Proposed Sale	$199.83	2,660	531,548	0
Singhal Priya	Head of Development	Feb 09 '26	Sale	$199.83	2,660	531,548	8,043

Biogen Inc Aktie (BIIB) Neueste Nachrichten

Oct 28, 2026

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Zacks Investment Research

Oct 28, 2026

Big Day for Econ Data, Hyperscaler Earnings - Zacks Investment Research

Oct 28, 2026

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

Oct 28, 2026

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Boeing Stock Drops 7.5% After Q3 Earnings Miss Erases $10 Billion - 24/7 Wall St.

Oct 27, 2026

Biogen schedules October 28 results. Biogen stock trades 0.62 percent below its 52-week high - ad-hoc-news.de

Oct 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Oct 27, 2026

Oct 26, 2026

Baron Health Care Fund: Q3 2026 New Positions And Exits - Seeking Alpha

Oct 26, 2026

Oct 23, 2026

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? - Zacks Investment Research

Oct 23, 2026

Oct 22, 2026

Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.

Oct 22, 2026

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Oct 22, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Oct 21, 2026

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Oct 21, 2026

Oct 20, 2026

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research

Oct 20, 2026

Oct 19, 2026

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research

Oct 19, 2026

Oct 14, 2026

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026

Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.

Oct 07, 2026

Oct 06, 2026

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 06, 2026

Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.

Oct 06, 2026

Oct 05, 2026

Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media

Oct 05, 2026

Oct 02, 2026

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research

Oct 02, 2026

Sep 26, 2026

Form 4 Boeing Co For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Form 4 Boeing Co For: 26 September - Investing.com India

Sep 26, 2026

Sep 24, 2026

Boeing Company (BA) Stock News & Articles - 247wallst.com

Sep 24, 2026

Sep 23, 2026

Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 23, 2026

Sep 20, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool

Sep 20, 2026

Sep 16, 2026

Is Biogen Stock Outperforming the S&P 500? - Barchart.com

Sep 16, 2026

Sep 12, 2026

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Sep 11, 2026

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Sep 11, 2026

Sep 10, 2026

Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com

Sep 10, 2026

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com

Sep 10, 2026

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 10, 2026

BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus

Sep 10, 2026

Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de

Sep 10, 2026

Stifel reiterates Biogen stock rating on immunology pipeline - investing.com

Sep 10, 2026

Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada

Sep 10, 2026

Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com

Sep 10, 2026

Sep 09, 2026

Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media

Sep 09, 2026

Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada

Sep 09, 2026

Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com India

Sep 09, 2026

Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus

Sep 09, 2026

Sep 08, 2026

Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st

Sep 08, 2026

Ähnlich wie BIIB

Biogen Inc (BIIB)

Biogen Inc Aktie (BIIB) Unternehmensprofil

BIIB vs. LLY, JNJ, ABBV, MRK, NVS vergleichen

Biogen Inc Aktie (BIIB) Hochstufungen & Herabstufungen

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

Nettogewinn

Free Cashflow

ENV

Biogen Inc-Aktie (BIIB) Insiderhandel

Biogen Inc Aktie (BIIB) Neueste Nachrichten

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Zacks Investment Research

Big Day for Econ Data, Hyperscaler Earnings - Zacks Investment Research

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research

Boeing Stock Drops 7.5% After Q3 Earnings Miss Erases $10 Billion - 24/7 Wall St.

Biogen schedules October 28 results. Biogen stock trades 0.62 percent below its 52-week high - ad-hoc-news.de

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Baron Health Care Fund: Q3 2026 New Positions And Exits - Seeking Alpha

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? - Zacks Investment Research

Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Citigroup Drops 5% After Hours on Earnings Day - 24/7 Wall St.

Cisco Systems (CSCO) Stock Price, News & Analysis - 24/7 Wall St.

Lori Trahan Stock Trades and Disclosures - TechGraph

Daniel S Sullivan Stock Trades and Disclosures - TechGraph

Daniel S Sullivan Stock Trades and Disclosures - TechGraph

Form 4 Boeing Co For: 7 October By Investing.com - Investing.com UK

Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.

Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research

Form 4 Boeing Co For: 26 September By Investing.com - Investing.com Nigeria

Form 4 Boeing Co For: 26 September - Investing.com India

Boeing Company (BA) Stock News & Articles - 247wallst.com

Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool

Is Biogen Stock Outperforming the S&P 500? - Barchart.com

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st

Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus

Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de

Stifel reiterates Biogen stock rating on immunology pipeline - investing.com

Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada

Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com

Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media

Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada

Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com India

Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus

Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st

Ähnlich wie BIIB